Tampa General Hospital Ranks Among Top 30% of Academic Medical Centers in the Nation
Vizient, Inc., Which Measures Safety and Quality Data Across the Nation's Acute Hospitals, Recognizes Tampa General as a Top Performer.
TAMPA, Fla., April 29, 2025 /PRNewswire/ — Vizient, Inc.'s annual rankings published Friday list Tampa General among the top 30% of the nation's leading hospitals for overall performance. The ranking demonstrates significant gains since Tampa General joined the cohort in 2017 at the 81st percentile.
'With technology, innovation and exceptional talent, Tampa General is continuously working to elevate quality, enhance safety and improve patient outcomes,' said John Couris, president and CEO of Tampa General Hospital. 'This monumental climb in rankings from Vizient is a testament to the relentless pursuit of exceptionalism by physicians, nurses and every member of our team, and it's an indication of the level of world-class care our patients receive when they seek care at Tampa General.'
Notably, Vizient ranks Tampa General in the top quartile for risk-adjusted mortality rate (13th percentile) and length of stay (21st percentile) when measured against other academic medical centers in the nation that care for patients with the rarest and most complex diseases and conditions.
'I'm grateful to our faculty physician leaders, who commit to providing the highest level of health care to our patients every day,' said Charles J. Lockwood, M.D., MHCM, executive vice president at USF Health, dean of the USF Health Morsani College of Medicine, and executive vice president and chief academic officer at Tampa General. 'Their expertise and dedication to advancing complex, multi-disciplinary, cutting-edge care shows why academic medicine delivers lifesaving care and the best outcomes for our patients.'
The Vizient Quality and Accountability Study measures safety, mortality and efficiency, among other metrics, across 118 comprehensive academic medical centers, including NYU Langone, Mass General Brigham and Vanderbilt University. Tampa General is the only system in Tampa Bay that participates in Vizient's cohort of large academic medical centers.
'Tampa General is one of the nation's leading academic health systems,' said Peggy Duggan, M.D., executive vice president, chief physician executive and chief medical officer at Tampa General. 'Compared with other academic medical centers, Vizient confirms TGH truly is one of the best among the best.'
Vizient analyzes data to evaluate performance and outcomes while accounting for the complex nature of services provided and patients in treatment at academic medical centers.
Academic medical centers are comprehensive organizations that combine education, research and clinical expertise to provide the most advanced forms of health care. The tertiary and quaternary care at academic medical centers include complex surgery, such as neurosurgery, cardiothoracic, and transplantation, as well as neonatology, cancer care, intensive care, palliative care, and many other complex medical and surgical interventions, including experimental treatments and procedures.
'This strong performance ranking is not just good for our system, it's excellent for our patients,' said Laura Haubner, M.D., senior vice president and chief quality officer at Tampa General. 'In simple terms, a lower mortality rate means more lives are saved. A shorter length of stay means patients recover and return home faster.'
Tampa General's high-performance ranking from Vizient is the latest in a long list of accolades from trusted, third-party organizations that evaluate health care organizations. Other recent rankings include:
Tampa General is consistently ranked among the nation's best hospitals by U.S. News & World Report and among the 'World's Best Hospitals' by Newsweek. Tampa General is the only academic health system in the country that has received two key safety qualifications from the international accreditation organization DNV (dnv.us). Tampa General Hospital has earned Magnet® designation status five times in a row for excellence in nursing, a recognition achieved by less than 2% of hospitals nationwide.
ABOUT TAMPA GENERAL HOSPITAL
Tampa General Hospital, a 981-bed, not-for-profit, academic health system, is one of the largest hospitals in America and delivers world-class care as the region's only center for Level l trauma and comprehensive burn care. Tampa General Hospital is the highest-ranked hospital in the market in U.S. News & World Report's 2024-2025 Best Hospitals, with two medical specialties ranking among the top 20 in the nation and eight medical specialties ranking among the top 50 best hospital programs in the United States. Tampa General Hospital has been designated as a model of excellence by the 2022 Fortune/Merative 100 Top Hospitals list. The academic health system's commitment to growing and developing its team members is recognized by three prestigious Forbes magazine rankings – in the top 100 nationally in the 2024 America's Best Large Employers, the top 50 in Florida in the 2024 America's Best Employers by State and the 2023 America's Best Employers for Women. Tampa General is the safety net hospital for the region, caring for everyone regardless of their ability to pay, and in fiscal year 2023, provided a net community benefit of approximately $301.8 million in the form of health care for underinsured patients, community education, and financial support to community health organizations in Tampa Bay. It was the nation's busiest adult solid organ transplant center in 2024 and is the primary teaching hospital for the USF Health Morsani College of Medicine. With five medical helicopters, Tampa General Hospital transports critically injured or ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General houses a nationally accredited comprehensive stroke center, and its 32-bed Neuroscience, Intensive Care Unit is the largest on the West Coast of Florida. It also is home to the Muma Children's Hospital at TGH, the Jennifer Leigh Muma 82-bed neonatal intensive care unit, and a nationally accredited rehabilitation center. Tampa General Hospital's footprint includes TGH North, which is comprised of three hospitals and several outpatient locations in Citrus and Hernando counties, 17 Tampa General Medical Group Primary Care offices, TGH Family Care Center Kennedy, two TGH Outpatient Centers, TGH Virtual Health, and 19 TGH Imaging outpatient radiology centers throughout Hillsborough, Pasco, Pinellas and Palm Beach counties. Tampa Bay area residents also receive world-class care from the TGH Urgent Care powered by the Fast Track network of clinics. To see a medical care professional live anytime, anywhere on a smartphone, tablet or computer, visit Virtual Health | Tampa General Hospital (tgh.org). As one of the largest hospitals in the country, Tampa General Hospital is the first in Florida to open a clinical command center that provides real-time situational awareness to improve and better coordinate patient care at a lower cost. For more information, go to www.tgh.org.
ABOUT USF HEALTH
USF Health's mission is to envision and implement the future of health. It is the partnership of the USF Health Morsani College of Medicine, the College of Nursing, the College of Public Health, the Taneja College of Pharmacy, the School of Physical Therapy and Rehabilitation Sciences, the Biomedical Sciences Graduate and Postdoctoral Programs, and USF Health's multispecialty physicians' group. The University of South Florida, a high-impact research university dedicated to student success and committed to community engagement, generates an annual economic impact of more than $6 billion. Through hundreds of millions of dollars in research activity each year, USF is a leader in solving global problems and improving lives. For more information, visit health.usf.edu.
Media Contact:
USF Health Media Contact: Cody Hawley
Amanda Bevis
Senior Director
(202) 680-9262
USF Health Communications & Marketing
Amanda@redhillsfl.com
crhawley@usf.edu
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 days ago
- Malaysian Reserve
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough. Conference Call/WebcastThe Company will host a conference call and webcast to review the topline results. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About Idiopathic Pulmonary Fibrosis (IPF) Chronic CoughChronic cough is a highly prevalent condition in patients with IPF, impacting up to 85% of the IPF population. There are ~140,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Investor ContactJonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media ContactRosalia Scampoli914-815-1465rscampoli@
Malaysian Reserve
28-05-2025
- Malaysian Reserve
Tolmar Pharmaceuticals Canada Appoints Mike Patterson as General Manager
MISSISSAUGA, ON, May 27, 2025 /CNW/ – Tolmar Pharmaceuticals Canada, Inc. (Tolmar Pharmaceutiques Canada, Inc.) is pleased to announce the appointment of Mike Patterson as General Manager effective immediately. Mike brings more than 20 years of diverse leadership experience in the pharmaceutical industry, with a strong record of commercial success across sales, marketing, operations, market access, and business strategy. He has held senior leadership roles at global, mid-sized, and emerging companies, consistently driving progress across oncology, rare diseases, specialty care, and primary care. Most recently, Mike served as Vice President, Business Operations & Strategy and Chief of Staff to the CEO at Ipsen North America. In this role, he led strategic transformation efforts and supported the successful execution of multiple product launches and acquisitions. Previously, as Head of the Oncology Business Unit at Ipsen Canada, Mike played a key role in advancing access to therapies through strong collaboration with healthcare professionals and payors. He is known for building high-performing teams and finding creative, patient-focused strategies by working closely with government stakeholders and healthcare providers to enhance the quality of care across the country. 'I'm honored to join Tolmar at such a pivotal moment for the organization,' said Mike Patterson, General Manager, Canada. 'I look forward to partnering with our teams and the broader healthcare community to advance patient care and bring Tolmar's innovative therapies to more Canadians.' 'Mike's appointment comes at a time of important momentum for Tolmar in Canada,' said Michele Mazzaccaro, Senior Vice President, North America, Commercial Strategy. 'As we continue to expand our footprint, our mission remains clear: to deliver impactful, high-quality therapies to more Canadians. Mike's deep commitment to patient access, combined with his ability to drive growth through meaningful partnerships, makes him the right leader to help us reach more patients with the care they need'. Mike holds an Honours B.A. in Kinesiology from Western University and has completed executive leadership and coaching programs through MIT and IMD Business School in Switzerland. About Tolmar Tolmar Pharmaceuticals Canada, Inc. is a subsidiary of Tolmar International Limited – a fully-integrated pharmaceutical company focused on the innovative development, approval, manufacturing, and commercialization of specialty pharmaceuticals across multiple therapeutic areas, including Oncology, Urology, and Endocrinology. Tolmar's heritage is rooted in its proprietary drug delivery technologies and its deep commitment to patients, providers, and improving therapeutic outcomes. Headquartered in Ireland, Tolmar operates globally with products available in more than 60 countries. For more information about the company, please visit
Malaysian Reserve
28-05-2025
- Malaysian Reserve
Portal Access, Inc. Announces the closing of $7 Million Series A Financing Round to Support FDA Approval and Limited Market Launch of Next-Generation Chemotherapy Port
MIAMI, May 27, 2025 /PRNewswire/ — Portal Access, Inc., a medical device start-up company pioneering next-generation advanced vascular access solutions for oncology, announced the successful closing of a $7 million Series A financing round today. The round was fully subscribed, reflecting strong investor support for the company's vision and technology. Over 80% of the round was led by U.S physician investors including oncologists, interventional radiologists, cardiologists, vascular surgeons and others, in addition to a partnership from a U.S based venture capital fund; underscoring strong clinical conviction and belief in the device's potential to modernize cancer care drug delivery. The funds will support regulatory activities and the planned 510(k) submission for approval to the U.S. Food and Drug Administration (FDA) for Flexi-Port™ SLF-TANL™, a novel subcutaneous port designed to simplify vascular access for oncology patients and a limited market launch. 510(k) submission is expected July 2025 and U.S market launch is anticipated in early 2026. The device is intended to enhance usability, reduce complexity, broaden accessibility and decrease costs. Dr. Michael Tal, Founder and CEO of PorTal Access Inc. says 'Closing this funding round represents an important milestone as we work toward regulatory approval. Flexi-Port™ SLF-TANL™ is engineered with a focus on simplicity, stability, and scalability — likely to support more efficient workflows in oncology access settings. It's a solution for both clinicians and patients and created with the most optimal patient outcome and experience in mind.' Despite being the standard of care, it is estimated that nearly half of cancer patients do not receive a chemo-port due to various reasons like delay in treatment. By simplifying access and potentially enabling placement in additional care settings, The Flexi-Port™ SLF-TANL™ device may help reduce treatment delays, procedural risks, and overall healthcare costs — improving the patient experience and operational efficiency across cancer care delivery. 'I have used the Flexi-Port SLF-TANL to provide chemotherapy in some of the most vulnerable patients and it has consistently exceeded expectations,' says Matthew Ostroff, RN, MSN, AGACNP, VABC, a pioneer in the field of bedside vascular access. 'Its innovative self-tunneling technology is a revolutionary advancement offering a less invasive option that can be placed safely at the bedside or in an outpatient setting. From a clinical perspective, this technology has the potential to transform the standard of care in port placement – offering patients a more dignified, convenient, and compassionate experience at a time when it matters most.' Angela Dotson, Executive VP of Business Development at PorTal Access, Inc. said, 'In my career, I have never witnessed this level of enthusiasm from physicians for a medical technology. During our Series A round, the demand for the Flexi-Port™ SLF-TANL™ was overwhelming—$6 million of our funding came directly from individual physician investors. This type of physician-driven investment is both remarkable and virtually unprecedented. From a market development perspective, the response has been equally compelling. We are seeing significant interest from clinics and hospitals across the country, many of which are already preparing to integrate the Flexi-Port™ SLF-TANL™ into their practice as soon as it becomes available. They've been waiting more than 30 years for an innovation like this. Today, we are one step closer to delivering this transformative solution to clinicians and their patients.' About PorTal Access, Inc.:PorTal Access, Inc. is committed to designing solutions that aim to reduce complications currently associated with chemo port placement while offering a safe and minimally invasive option for bedside or in an outpatient setting. Flexi-Port™ SLF-TANL™ is currently not available for sale. For more information or to be added to our market launch, please contact:Angela DotsonExecutive VP Business Development540-817-5515angeladotson@
